Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy
Toshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, et al.
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 7, pp. 877-890
Closed Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi, Dechao Jiao, Hanxiao Xu, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 668
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Xinxin Zhu, Jinghe Lang
Oncotarget (2017) Vol. 8, Iss. 57, pp. 97671-97682
Open Access | Times Cited: 279
Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type
Motoko Yamaguchi, Ritsuro Suzuki, Masahiko Oguchi
Blood (2018) Vol. 131, Iss. 23, pp. 2528-2540
Open Access | Times Cited: 199
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, R. A. Velichinskii, Randy W. Lesh, et al.
Advances in Therapy (2019) Vol. 36, Iss. 10, pp. 2638-2678
Open Access | Times Cited: 172
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 117
Molecular pathogenic pathways in extranodal NK/T cell lymphoma
Sanjay De Mel, Susan Swee-Shan Hue, Anand D. Jeyasekharan, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 115
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
Boyang Chang, Tao Huang, Huajun Wei, et al.
Cancer Immunology Immunotherapy (2018) Vol. 68, Iss. 3, pp. 353-363
Open Access | Times Cited: 112
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, et al.
Blood (2020) Vol. 136, Iss. 24, pp. 2754-2763
Open Access | Times Cited: 105
NK-/T-cell lymphomas
Hua Wang, Bibo Fu, Robert Peter Gale, et al.
Leukemia (2021) Vol. 35, Iss. 9, pp. 2460-2468
Open Access | Times Cited: 101
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress
Yasuaki Harabuchi, Miki Takahara, Kan Kishibe, et al.
Frontiers in Pediatrics (2019) Vol. 7
Open Access | Times Cited: 92
Towards translation of surface-enhanced Raman spectroscopy (SERS) to clinical practice: Progress and trends
Sandeep Surendra Panikar, Dana Cialla‐May, E. De la Rosa, et al.
TrAC Trends in Analytical Chemistry (2020) Vol. 134, pp. 116122-116122
Closed Access | Times Cited: 89
Epstein–Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach
Susan Swee-Shan Hue, Ming Liang Oon, Shi Wang, et al.
Pathology (2019) Vol. 52, Iss. 1, pp. 111-127
Closed Access | Times Cited: 88
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Muhammad Saleem Iqbal Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 79
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N. Nora Bennani, Hyo Jin Kim, Levi D. Pederson, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004984-e004984
Open Access | Times Cited: 54
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Yue Pan, Yucheng Fu, Yue Zeng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 45
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
Huiqiang Huang, Rong Tao, Siguo Hao, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 16, pp. 3032-3041
Open Access | Times Cited: 25
Therapeutic challenges in peripheral T-cell lymphoma
Yunpeng Luan, Xiang Li, Yunqi Luan, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 13
Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Tingkai Chen, Qi Li, Zongliang Liu, et al.
European Journal of Medicinal Chemistry (2018) Vol. 161, pp. 378-398
Closed Access | Times Cited: 80
Clinical significance of programmed cell death‐ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability
Shotaro Korehisa, Eiji Oki, Makoto Iimori, et al.
International Journal of Cancer (2017) Vol. 142, Iss. 4, pp. 822-832
Open Access | Times Cited: 66
Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
Jun Cai, Panpan Liu, Huiqiang Huang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 66
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors
Wei Wei, Bin Xu, Yan Wang, et al.
Medicine (2018) Vol. 97, Iss. 3, pp. e9617-e9617
Open Access | Times Cited: 60
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Kiyohiro Ando, Kazuyuki Hamada, Makoto Watanabe, et al.
Anticancer Research (2019) Vol. 39, Iss. 9, pp. 5195-5201
Open Access | Times Cited: 57
Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD‐1high Breg cells
Yu Mao, Yimin Wang, Lixin Dong, et al.
Cancer Science (2019) Vol. 110, Iss. 9, pp. 2700-2710
Open Access | Times Cited: 55
Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma
Mixue Xie, Xianbo Huang, Xiujin Ye, et al.
International Immunopharmacology (2019) Vol. 77, pp. 105999-105999
Closed Access | Times Cited: 55
Page 1 - Next Page

Scroll to top